Abstract
Noninvasive imaging assessment of tumor cell proliferation may be helpful in the evaluation of tumor growth potential, the degree of malignancy, and may provide an early assessment of treatment response prior to changes in tumor size determined by computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), or ultrasonography, respectfully. Understanding of tumor proliferative activity, in turn, could aid in the selection of optimal therapy by estimating patient prognosis and selecting the proper management. PET/CT imaging of 18F-fluoro-2-deoxy-glucose (FDG) is recognized as a technology for diagnosing the presence and extent of several cancer types. Recently, radiotracers beyond FDG were introduced as promising agents to increase specificity and to improve the accuracy of lesion size in oncology applications. These radiotracers were produced by using automated synthesizers to fulfill the current Good Manufacturing Practice (cGMP) guidelines. The devices are aimed at sterility and pyrogenicity requirements, batch-to-batch reproducibility, yield, purity, specific activity, fast synthesis time, and radiation protection. Through the use of automated devices, novel radiotracers may increase the specificity in oncology applications and can influence patient diagnosis, planning, and monitoring of cancer treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
